159 related articles for article (PubMed ID: 37925171)
21. Targeting SNORA38B attenuates tumorigenesis and sensitizes immune checkpoint blockade in non-small cell lung cancer by remodeling the tumor microenvironment via regulation of GAB2/AKT/mTOR signaling pathway.
Zhuo Y; Li S; Hu W; Zhang Y; Shi Y; Zhang F; Zhang J; Wang J; Liao M; Chen J; Qian H; Li D; Sun C
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35577506
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of PSAT1 is Correlated with Poor Prognosis and Immune Infiltration in Non-Small Cell Lung Cancer.
Li H; Wu C; Chang W; Zhong L; Gao W; Zeng M; Wen Z; Mai S; Chen Y
Front Biosci (Landmark Ed); 2023 Oct; 28(10):243. PubMed ID: 37919070
[TBL] [Abstract][Full Text] [Related]
23. Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies.
Larroquette M; Guegan JP; Besse B; Cousin S; Brunet M; Le Moulec S; Le Loarer F; Rey C; Soria JC; Barlesi F; Bessede A; Scoazec JY; Soubeyran I; Italiano A
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35618288
[TBL] [Abstract][Full Text] [Related]
24. Epidermal Growth Factor Receptor Mutations in Resectable Non-Small Cell Lung Cancer Patients and their Potential Role in the Immune Landscape.
Xia W; Mao W; Chen R; Lu R; Liu F; He Y; Wang S; Li X; Zheng M
Med Sci Monit; 2019 Nov; 25():8764-8776. PubMed ID: 31746315
[TBL] [Abstract][Full Text] [Related]
25. Effects of glucocorticoid use on survival of advanced non-small-cell lung cancer patients treated with immune checkpoint inhibitors.
Li N; Zheng X; Gan J; Zhuo T; Li X; Yang C; Wu Y; Qin S
Chin Med J (Engl); 2023 Nov; 136(21):2562-2572. PubMed ID: 37925595
[TBL] [Abstract][Full Text] [Related]
26. Nonsense mutation in pseudouridylate synthase 1 (PUS1) in two brothers affected by myopathy, lactic acidosis and sideroblastic anaemia (MLASA).
Fernandez-Vizarra E; Berardinelli A; Valente L; Tiranti V; Zeviani M
J Med Genet; 2007 Mar; 44(3):173-80. PubMed ID: 17056637
[TBL] [Abstract][Full Text] [Related]
27. Clinical Impact of Post-Progression Survival on Overall Survival in Elderly Patients with Non-Small-Cell Lung Cancer Harboring Sensitive EGFR Mutations Treated with First-Line EGFR Tyrosine Kinase Inhibitors.
Imai H; Yamada Y; Sugiyama T; Minemura H; Kaira K; Kanazawa K; Kasai T; Kaburagi T; Minato K;
Chemotherapy; 2018; 63(3):181-189. PubMed ID: 30107372
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
[TBL] [Abstract][Full Text] [Related]
29. Survival and soluble immune mediators of immune checkpoint inhibitor-induced interstitial lung disease in patients with non-small cell lung cancer.
Murata D; Azuma K; Murotani K; Matsuo N; Matama G; Tokito T; Sasada T; Hoshino T
Lung Cancer; 2023 Oct; 184():107351. PubMed ID: 37639819
[TBL] [Abstract][Full Text] [Related]
30. The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC.
Li X; Wang Y; Li X; Feng G; Hu S; Bai Y
Front Immunol; 2021; 12():638763. PubMed ID: 34305884
[TBL] [Abstract][Full Text] [Related]
31. The Roles and Mechanisms of TRAT1 in the Progression of Non-Small Cell Lung Cancer.
Guo Q; Wang SH; Ji YM; Tong S; Li D; Ding XC; Wu CY
Curr Med Sci; 2022 Dec; 42(6):1186-1200. PubMed ID: 36184729
[TBL] [Abstract][Full Text] [Related]
32. A Novel PUS1 Mutation in 2 Siblings with MLASA Syndrome: A Review of the Literature.
Oncul U; Unal-Ince E; Kuloglu Z; Teber-Tiras S; Kaygusuz G; Eminoglu FT
J Pediatr Hematol Oncol; 2021 May; 43(4):e592-e595. PubMed ID: 32287105
[TBL] [Abstract][Full Text] [Related]
33. The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis.
Wang C; Qiao W; Jiang Y; Zhu M; Shao J; Wang T; Liu D; Li W
J Cell Physiol; 2020 May; 235(5):4913-4927. PubMed ID: 31693178
[TBL] [Abstract][Full Text] [Related]
34. Long non-coding RNA SNHG6 promotes the growth and invasion of non-small cell lung cancer by downregulating miR-101-3p.
Li K; Jiang Y; Xiang X; Gong Q; Zhou C; Zhang L; Ma Q; Zhuang L
Thorac Cancer; 2020 May; 11(5):1180-1190. PubMed ID: 32147945
[TBL] [Abstract][Full Text] [Related]
35. A Multi-Omics Network of a Seven-Gene Prognostic Signature for Non-Small Cell Lung Cancer.
Ye Q; Falatovich B; Singh S; Ivanov AV; Eubank TD; Guo NL
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008645
[TBL] [Abstract][Full Text] [Related]
36. Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy.
Kotake M; Miura Y; Imai H; Mori K; Sakurai R; Kaira K; Tomizawa Y; Minato K; Saito R; Hisada T
Chemotherapy; 2017; 62(4):205-213. PubMed ID: 28380484
[TBL] [Abstract][Full Text] [Related]
37. Correlation Between Surrogate End Points and Overall Survival in a Multi-institutional Clinicogenomic Cohort of Patients With Non-Small Cell Lung or Colorectal Cancer.
Kehl KL; Riely GJ; Lepisto EM; Lavery JA; Warner JL; LeNoue-Newton ML; Sweeney SM; Rudolph JE; Brown S; Yu C; Bedard PL; Schrag D; Panageas KS;
JAMA Netw Open; 2021 Jul; 4(7):e2117547. PubMed ID: 34309669
[TBL] [Abstract][Full Text] [Related]
38. Integrative multiomics evaluation reveals the importance of pseudouridine synthases in hepatocellular carcinoma.
Jin Z; Song M; Wang J; Zhu W; Sun D; Liu H; Shi G
Front Genet; 2022; 13():944681. PubMed ID: 36437949
[No Abstract] [Full Text] [Related]
39. High UDG and BRCA1 expression is associated with adverse outcome in patients with pemetrexed treated non-small cell lung Cancer.
Hashemi Sadraei N; Feng Y; Du L; Fu P; Haque S; Dowlati A; Gollamudi J; Pennell NA; Mekhail T; Avril S; Farver C; Gerson SL; Sharma N
Lung Cancer; 2018 Dec; 126():48-54. PubMed ID: 30527192
[TBL] [Abstract][Full Text] [Related]
40. Pseudouridine synthase 1 deficient mice, a model for Mitochondrial Myopathy with Sideroblastic Anemia, exhibit muscle morphology and physiology alterations.
Mangum JE; Hardee JP; Fix DK; Puppa MJ; Elkes J; Altomare D; Bykhovskaya Y; Campagna DR; Schmidt PJ; Sendamarai AK; Lidov HG; Barlow SC; Fischel-Ghodsian N; Fleming MD; Carson JA; Patton JR
Sci Rep; 2016 May; 6():26202. PubMed ID: 27197761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
